Next Article in Journal
Regulation of DNA Damage Response by Estrogen Receptor β-Mediated Inhibition of Breast Cancer Associated Gene 2
Next Article in Special Issue
Editorial of Special Issue “New Aspects of the Hepatocyte Growth Factor/c-Met System”
Previous Article in Journal / Special Issue
HGF/Met-Signaling Contributes to Immune Regulation by Modulating Tolerogenic and Motogenic Properties of Dendritic Cells
Review

Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment

1
Department of Clinical Pharmacology, Modeling and Simulation, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA
2
Kite Pharma, Inc., 2225 Colorado Avenue, Santa Monica, CA 90404, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Giulia Ricci
Biomedicines 2015, 3(1), 149-181; https://doi.org/10.3390/biomedicines3010149
Received: 22 January 2015 / Revised: 25 February 2015 / Accepted: 3 March 2015 / Published: 19 March 2015
(This article belongs to the Special Issue New aspects of the Hepatocyte Growth Factor/c-Met System)
The hepatocyte growth factor (HGF): MET axis is a ligand-mediated receptor tyrosine kinase pathway that is involved in multiple cellular functions, including proliferation, survival, motility, and morphogenesis. Aberrancy in the HGF/MET pathway has been reported in multiple tumor types and is associated with tumor stage and prognosis. Thus, targeting the HGF/MET pathway has become a potential therapeutic strategy in oncology development in the last two decades. A number of novel therapeutic agents—either as therapeutic proteins or small molecules that target the HGF/MET pathway—have been tested in patients with different tumor types in clinical studies. In this review, recent progress in HGF/MET pathway-targeted therapy for cancer treatment, the therapeutic potential of HGF/MET-targeted agents, and challenges in the development of such agents will be discussed. View Full-Text
Keywords: HGF; MET; cancer treatment; new therapeutic agents; biomarker HGF; MET; cancer treatment; new therapeutic agents; biomarker
Show Figures

Graphical abstract

MDPI and ACS Style

Zhang, Y.; Jain, R.K.; Zhu, M. Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment. Biomedicines 2015, 3, 149-181. https://doi.org/10.3390/biomedicines3010149

AMA Style

Zhang Y, Jain RK, Zhu M. Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment. Biomedicines. 2015; 3(1):149-181. https://doi.org/10.3390/biomedicines3010149

Chicago/Turabian Style

Zhang, Yilong, Rajul K. Jain, and Min Zhu. 2015. "Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment" Biomedicines 3, no. 1: 149-181. https://doi.org/10.3390/biomedicines3010149

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop